We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Discoveries of Prostate Cancer Evolution Pave Way for Genetic Test

By LabMedica International staff writers
Posted on 01 Mar 2024

Prostate cancer ranks as one of the most common cancers affecting men, and while it accounts for a significant number of male cancer fatalities, many men live with it rather than die from it. More...

Understanding when to avoid unnecessary treatments is crucial, as it can prevent side effects like incontinence and impotence. Now, new research has identified two distinct subtypes of prostate cancer, referred to as evotypes. This discovery could lead to major advancements in the diagnosis and treatment of prostate cancer.

This discovery was made by an international consortium, called The Pan Prostate Cancer Group, which involved researchers from the University of Oxford (Oxford, UK), who used artificial intelligence (AI) to make new discoveries about the evolution of prostate cancer. Cancer development, like human evolution, can be traced and studied through its evolutionary history. By examining the cancer’s evolutionary tree, valuable insights about the disease can be gained, potentially aiding in the development of new treatments. The research involved an analysis of the DNA of prostate cancer samples from 159 patients through whole genome sequencing, a comprehensive method of examining an individual’s entire genetic material.

The team employed neural networks, an advanced AI technique, to compare the DNA of these samples. This analysis revealed two distinct cancer categories among the patients. These groups were further confirmed using two other mathematical methods applied to different data aspects. Moreover, this finding was corroborated in separate datasets from Canada and Australia. The researchers synthesized all this data to create an evolutionary tree depicting the development of the two prostate cancer subtypes, leading to the identification of two unique evotypes. Building on this discovery, the research team aims to develop a genetic test. This test, in conjunction with traditional staging and grading, could provide a more accurate prognosis for individual patients, enabling personalized treatment decisions. This innovation marks a significant leap forward in the field of prostate cancer research and treatment.

“Our research demonstrates that prostate tumors evolve along multiple pathways, leading to two distinct disease types,” said lead researcher Dr. Dan Woodcock, of the Nuffield Department of Surgical Sciences at the University of Oxford. “This understanding is pivotal as it allows us to classify tumors based on how the cancer evolves rather than solely on individual gene mutations or expression patterns.”

“This study is really important because until now, we thought that prostate cancer was just one type of disease. But it is only now, with advancements in artificial intelligence, that we have been able to show that there are actually two different subtypes at play,” said Professor Colin Cooper, from UEA’s Norwich Medical School. “We hope that the findings will not only save lives through better diagnosis and tailored treatments in the future, but they may help researchers working in other cancer fields better understand other types of cancer too.”

Related Links:
University of Oxford


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Drug Test Kit
DrugCheck 3000
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.